Get the Stockscreener App
8.12
0.25%
0.02
After Hours:
8.10
-0.02
-0.25%
Overview
News
Price History
Option Chain
Why GRFS Down?
Discussions
Forecast
Stock Split
Dividend History
Grifols Sa Adr Stock (GRFS) Latest News
Deutsche Bank raises Grifols SA price target to EUR11.00 - Investing.com India
Grifols: Looking At The Longer-Term 2025-2027 Upside After No Sale (GRFS) - Seeking Alpha
Get in on Grifols SA ADR’s (GRFS) buy-in window today! - SETE News
Wall Street analysts’ outlook for Douglas Elliman Inc (DOUG) - SETE News
Financial Metrics Exploration: Understanding Accuray Inc (ARAY) Through Ratios - The Dwinnex
Financial Fitness Check: Examining Mannkind Corp (MNKD)’s Key Ratios - The Dwinnex
Orphan Designated Drugs Market Analysis: Key Trends, Players and Forecasts for Future Growth - GlobeNewswire Inc.
Grifols: More Attractive Than In A Very Long Time (NASDAQ:GRFS) - Seeking Alpha
Grifols Stock Declines After Brookfield Drops Buyout Offer - Barchart
BRF S.A. goes ex dividend tomorrow - MSN
Brookfield Drops $6.8 Billion Offer to Buy Drugmaker Grifols - BNN Bloomberg
Grifols slips as board rebuffs Brookfield’s $6.8B offer (update) - MSN
Grifols' Board Rejects Brookfield's Buyout Offer, Stock Down 8% - MSN
Grifols falls amid potential Moody's downgrade, new short report - MSN
Grifols stock slips as Brookfield offer rebuffed (GRFS:NASDAQ) - Seeking Alpha
Is it possible to buy Grifols SA ADR(GRFS) shares at a good price now? - US Post News
Grifols SA ADR (GRFS)’s Day in Review: Closing at 8.58, Down by -0.12 - The Dwinnex
RFID Kanban Systems Market Forecast to Reach $9.53 Billion by 2030 - GlobeNewswire Inc.
A Look at Grifols SA ADR (GRFS) Shares in the Recent Past Indicates Growth - SETE News
Cboe Global Markets Inc. (AMEX: CBOE): Getting A Free Pass? - Stocks Register
It is Poised to be a Bull Market for Grifols SA ADR (GRFS) - SETE News
Grifols: Here Is Why It's Still A 'Buy' Even If Price Goes Down (NASDAQ:GRFS) - Seeking Alpha
Examining Grifols SA ADR (GRFS) stock is warranted - US Post News
Are Grifols SA ADR’shares a good deal? - US Post News
Orange To Delist From NYSE To Reduce Financial Burdens - Yahoo Finance
Financial Health Report: Grifols SA ADR (GRFS)’s Ratios Tell a Tale - The Dwinnex
Was anything negative for Grifols SA ADR (GRFS) stock last session? - US Post News
Ratio Review: Analyzing Grifols SA ADR (GRFS)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
GRFS’s Stock Market Puzzle: Piecing Together 2023’s Performance - The InvestChronicle
How does Grifols SA ADR (GRFS) change from a tortoise to a hare? - SETE News
Mexico Blood Transfusion Diagnostics Market Size & Outlook, 2027 - Grand View Research
Have you been able to find a good deal on Grifols SA ADR’s shares? - US Post News
UK Intravenous Immunoglobulin Market Size & Outlook, 2030 - Grand View Research
Grifols Class B stock falls as Brookfield reportedly seeks lower price - MSN
Grifols Class B stock discounted by Brookfield (NASDAQ:GRFS) - Seeking Alpha
The UAE Blood Transfusion Diagnostics Market Size & Outlook, 2027 - Grand View Research
Grifols SA ADR (GRFS)’s Market Momentum: Closing Strong at 9.00, Up 2.74 - The Dwinnex
Grifols SA ADR (GRFS) looking to reclaim success with recent performance - SETE News
Why Grifols (GRFS) Stock Price Moved Up 7% on Wednesday - Yahoo Finance
Grifols shares up on potential takeover by Brookfield - Investing.com
China Intravenous Immunoglobulin Market Size & Outlook, 2030 - Grand View Research
India Blood Transfusion Diagnostics Market Size & Outlook, 2027 - Grand View Research
Validea Joseph Piotroski Strategy Daily Upgrade Report8/6/2024 - Nasdaq
Grifols revises past financial records with equity value drop of $494 mln - Marketscreener.com
Grifols: Going Private? Brookfield On The Scene (OTCMKTS:GIFLF) - Seeking Alpha
Grifols receives takeover interest from its founding family, Brookfield fund; to go private - Seeking Alpha
Grifols, S.A. (BME:GRF) most popular amongst retail investors who own 45% of the shares, institutions hold 35% - Simply Wall St
Grifols shares fall after new Gotham City Research report - Marketscreener.com
Grifols 2023 Annual Report on Form 20-F filed with the SEC - PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Grifols S.A.GRFS - PR Newswire
AMBAR, an Encouraging Alzheimer's Trial That Raises Questions - Frontiers
The 10 Most-Bought and Most-Sold European Stocks - Morningstar
Grifols sees China stake sale going ahead despite Gotham City report - Reuters
BreakingviewsShort attack intensifies Grifols’ health problem - Reuters
Grifols launches new solution to facilitate pre-transfusion compatibility testing in multiple myeloma patients - PR Newswire UK
Grifols 2022 Annual Report on Form 20-F filed with the SEC on April 18, 2023 - PR Newswire
Novo Nordisk A/s Dividend History & Dividend Yield 2024 - INDmoney
Victor Grifols Roura decides to retire as Chairperson; Grifols appoints private equity veteran Steven F. Mayer as Executive Chairperson - PR Newswire
Grifols enters into agreement with Canadian Blood Services to accelerate self-sufficiency in immunoglobulins for Canada - PR Newswire
2.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):